Kornimate/medical-research-clean huggingface dataset:
regeneten patch vs standard care in partial thickness rotator cuff repair

Conditions: Rotator Cuff Tears; Shoulder Surgery

Summary: shoulder pain is a common complaint with the most common reason being tendinopathy and/or tearing of the rotator cuff. while many rotator cuff tears are often considered normal, age-related degenerative disorders, with either partial- or full-thickness rotator cuff tears evident in 4% of patients aged \ 60 years, once they become symptomatic and conservative management fails, they are typically repaired surgically. data suggest that the incidence of surgery to repair and re-attach the cuff continues to rise. however, despite positive clinical results overall, reports of repair failure after surgery can range from 16%-94%, and of those that do fail, or fail to heal, generally do so within the first 3 to 6 months post-surgery. given the aforementioned reported issues with the gold standard for the treatment of unresponsive and symptomatic partial or full rotator cuff tears (surgical repair), together with the invasiveness of this surgery and lengthy period of restricted activity, other means of treatment have been proposed. the regeneten scaffold/implant seeks to support new tendon growth and disrupt disease progression. this study seeks to investigate the outcome of surgical rotator cuff repair versus scaffold augmentation (using the regeneten scaffold) for symptomatic partial thickness rotator cuff tears.


Eligibility criteria:
inclusion criteria: * males and females aged 40-75 years with a partial-thickness rotator cuff tear (50% or more) confirmed on mri scan that, in combination with patient-report symptoms and clinical examination by the orthopaedic surgeon, would confirm the rotator cuff tear as the primary pathology driving pain, symptoms and functional disability . * symptoms \> 3 months * unsuccessful conservative treatment comprising of a corticosteroid injection (into the subacromial bursa) and physiotherapy (while it is acknowledged that a range of modalities may be available to patient's presenting with apparent symptomatic rotator cuff pathology, for the current study, physiotherapy has been defined specifically as a course of 'exercise-based' therapy specific to the individual patient, though generally comprising of exercises designed to strengthen the rotator cuff and scapula stabilizing musculature, improving flexibility and shoulder mobility) exclusion criteria: * revision surgery * cervical pathology * adhesive capsulitis * multi-tendon tears * concomitant upper limb pathology (eg: arthritis, nerve compression) * infection * previous fracture * instability * pregnancy and lactation * professional athlete * worker's compensation or compensable claim * substance abuse or current mental illness * smoker * adverse reaction to bovine derived products
epidemiology of intracerebral hemorrhage

Conditions: ICH - Intracerebral Hemorrhage

Summary: exploring the risk factors and associations of intracerebral hemorrhage

exploring the clinical characteristics and prevalence of intracerebral hemorrhage in assiut university

Eligibility criteria:
inclusion criteria: * both sex * age ≥ 18 * patients diagnosed with non traumatic hemorrhagic stroke on brain computed tomography scan exclusion criteria: * presence of space occupying lesion visible on brain computed tomography scan * preceding brain trauma or post traumatic cerebral hemorrhagic stroke * presence of ischemic stroke * presence hemorrhagic transformation on top of acute ischemic stroke

Keywords: prevalence ich
cd4^lvfoxp3 in participants with ipex

Conditions: IPEX

Summary: this first-in-human, phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of cd4\^lvfoxp3 in up to 30 evaluable human participants with ipex and evaluate the impact of the cd4\^lvfoxp3 infusion on the disease.

treatment with cd4\^lvfoxp3 is expected to replace the defective treg cells of the participants, and restore control of the immune system and therefore ameliorate symptoms of ipex. we expect to learn the following from this study: 1. that cd4\^lvfoxp3 can be consistently produced and be of expected quality to be used in humans, 2. that cd4\^lvfoxp3 are safe in children and young adults with ipex, and determine its effects, both good and bad, 3. that cd4\^lvfoxp3 can improve overall health and allow reduction of medication/s. this phase 1 (feasibility and safety) trial will gather data about cd4\^lvfoxp3 in vivo persistency and early signs of impact on symptoms of ipex.

Eligibility criteria:
inclusion criteria: * body weight greater than 8 kg, unless assessed as able to tolerate leukapheresis * foxp3 gene mutation * medical history of progressive symptoms of ipex with persistency of some symptoms and/or signs requiring immune suppressive medication. the participant may or may not be on immunosuppression at time of starting the study. * uncontrolled ipex disease but unable to tolerate immune suppressive medication * recurrent ipex symptoms, requiring immune suppressive medications, in participants who have had prior allogeneic (allo) blood stem cell transplantation (hsct). * ≥ 50% performance rating on lansky/karnofsky scale * organ and marrow function within acceptable levels of function * absence of ongoing infections * must be able to consent if an adult exclusion criteria: * medical instability * less than 6 months life expectancy * inability to meet limits for steroid dosing * eligible for an hla matched sibling or matched unrelated donor blood stem cell transplant, and be willing to undergo transplant. * unrelated or comorbid disease * allergy to any study medication, product, or intervention * currently receiving another experimental treatment * history of malignancy, unless disease free for at least 2 years, with the exception of non melanoma skin cancer or carcinoma in situ

Keywords: treg cells regulatory t cells gene therapy autoimmunity immune dysregulation polyendocrinopathy enteropathy x-linked foxp3 lentiviral cd271 ngfr immune suppression
a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous nnc0143-0406 a 0.6 mmol/l in subjects with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe. the aim of the trial is to investigate the safety, tolerability,pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneous nnc0143-0406 a 0.6 mmol/l in subjects with type 1 diabetes


Eligibility criteria:
inclusion criteria: * male, aged 18-55 years (both inclusive) at the time of signing informed consent * subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening * body mass index between 18.5 and 28.0 kg/m\^2 (both inclusive) exclusion criteria: * known or suspected hypersensitivity to trial product(s) or related products. * males who are sexually active and not surgically sterilised (vasectomy or otherwise) and their partners that are not using a highly effective contraception method, from randomisation until 90 days after dosing, such as double barrier contraception (e.g. condom and spermicide) or combination of either an oral contraceptive, a contraceptive patch, a diaphragm or intrauterine device, together with a physical barrier such as condom. malesubjects must also agree to refrain from sperm donation from randomisation until 90 days after dosing * history or presence of any clinically relevant respiratory, metabolic (including dyslipidaemia), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus) * subject who has donated any blood or plasma in the past month or more than 500 ml within 90 days prior to screening * smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking or use of nicotine gum or transdermal nicotine patches during the in-patient period * recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the last 180 days
a castor bean solution for cleaning dentures

Conditions: Prostheses-related Infections

Summary: to evaluate the efficacy of a castor bean-based solution (ricinus communis) for removal of complete denture biofilm, comparing it with two products available on the market (sodium hypochlorite and alkaline peroxide). fifty complete maxillary denture-wearers were instructed to brush their dentures after meals and once a day, for a period of 07 days, immerse them in the following solutions: a - control: physiological solution(20 minutes). b - polident alkaline peroxide(3 minutes). c - 1% sodium hypochlorite(20 minutes). d - castor bean-based solution(20 minutes). the participants immersed their dentures in each of the solutions, according to a randomized sequence. for biofilm quantification, before (baseline) and after the use of each product, the internal surfaces of maxillary complete dentures were revealed (1% neutral red), photographed and the stained biofilm was quantified with the aid of software (image tool 3.0). after concluding measurements of the areas (total and biofilm), the percentage of surface covered by biofilm of the complete denture was calculated .

the study sought to minimize the occurrence of bias, and whenever possible sought to "blind" the parties involved (researchers, volunteers and statisticians), since none of them had knowledge of the allocation of treatments. the present study also followed the criteria described in the consort declaration

Eligibility criteria:
inclusion criteria: * adult patients of both genders, age-range 45 years and over, completely edentulous, in a good state of general health, wearers of maxillary complete dentures fabricated of heat polymerized acrylic resin and acrylic artificial teeth. exclusion criteria: * dentures that had been used for less than 03 years, and broken, fractured or relined dentures.

Keywords: biofilm, castor bean, sodium hypochlorite, alkaline peroxide
effect of the cognitive strategy during trunk muscle endurance in patients with lumbar hernia surgery

Conditions: Low Back Pain; Disk Herniated Lumbar

Summary: muscle endurance will be evaluated on two exercises: biering-sorensen test and prone plank test. each test will be assessed in different days following a randomized order.

all patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position. each exercise will perform under two conditions. on the control condition, the patients will perform both tests without any cognitive condition, while on the experimental condition they will be instructed to perform both tests while performing a mathematical subtracting task (starting at 300, by sevens). the starting condition will be randomly assigned with a 5-minute rest prior to the next condition. time to task failure and pain perception using a visual analog scale will be assessed.

Eligibility criteria:
inclusion criteria: * age between 20-50 years. * surgery of lumbar discectomy or lumbar arthrodesis with at least 3 months of evolution. * acceptance to participate in the study. exclusion criteria: * history of previous surgery in the lower extremities. * recent trauma (\<6 months). * use of corticosteroids. * pregnancy. * cauda equina syndrome. * marrow-level lesions. * progressive neurological involvement. * history of rheumatological diseases. * inability to perform the test measurement.

Keywords: muscle endurance biering-sorensen test prone plank test. dual task time to failure
clinical evaluation of flacs with combination of lensx® and centurion®

Conditions: Cataract

Summary: the purpose of this study is to evaluate cumulative dissipated energy (cde), endothelial cell loss, and average torsional amplitude with combination of lensx® and centurion® compared to conventional cataract surgery.

subjects will attend 7 scheduled visits: 1 pre-operative, 1 operative, and 5 post-operative.

Eligibility criteria:
inclusion criteria: * cataracts (grade 2-4 of emery-little classification) with planned cataract removal by phacoemulsification in both eyes; * able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures; * calculated lens power within the available range; * other protocol-specified inclusion criteria may apply. exclusion criteria: * any pathology that could reduce visual potential; * hypotony or the presence of a corneal implant; * residual, recurrent, active ocular or eyelid disease; * poorly dilating pupil; * any contraindication to cataract; * eyes with two different levels of cataract grade; * pregnant, or planned pregnancy during the study; * expected to require an ocular surgical treatment at any time during the study; * other protocol-specified exclusion criteria may apply.
personalized noninvasive support

Conditions: Acute Hypoxic Respiratory Failure

Summary: the optimal noninvasive respiratory support for acute hypoxemic respiratory failure is debated. recent preliminary data indicate that both pressure-support noninvasive ventilation (niv) and continuous-positive airway pressure (cpap) may be of benefit. while often applied interchangeably in clinical practice, niv and cpap have different effects on the inspiratory effort, which is the major determinant of self-inflicted lung injury. also, inspiratory effort widely varies among individuals. the purpose of this study is to assess the physiological effects of a noninvasive respiratory support approach guided by inspiratory effort, as compared to cpap and niv, in patients with moderate-to-severe acute hypoxemic respiratory failure.

patients with acute hypoxemic respiratory failure will undergo a decremental pressure-support trial during helmet noninvasive support. the following pressure-support settings will be applied sequentially, with positive end-expiratory pressure kept constant and equal to 10-12 cmh2o: 20 cmh2o, 16 cmh2o, 12 cmh2o, 8 cmh2o and high-flow-driven cpap. inspiratory effort will be monitored during the trial through esophageal manometry. the personalized setting of noninvasive support will be defined as the minimal pressure-support level capable of generating inspiratory effort between 5 and 10 cmh2o. personalized noninvasive support will be then compared to conventionally-set niv and cpap in a randomized cross-over trial.

Eligibility criteria:
inclusion criteria: * acute hypoxemic respiratory failure and pao2/fio2\<200 mmhg * paco2\<45 mmhg * respiratory failure not caused by exacerbation of chronic pulmonary disease, cardiac failure or fluid overload exclusion criteria: * pregnancy * contraindication to helmet support * contraindication to esophageal manometry * contraindication to electrical-impedance tomography monitoring * recent surgery involving the abdomen or the thorax * pneumothorax or documented barotrauma
evaluating a telemedicine neurological consult program for drug-induced movement disorders using the re-aim framework

Conditions: Drug-Induced Movement Disorder

Summary: in this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (dimds). dimds can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in parkinson's disease and further validation in other movement disorders is necessary. in this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with dimds either in-person or through telemedicine. the investigators will apply the evaluation framework re-aim (reach and effectiveness, adoption, implementation, and maintenance) to comprehensively assess the factors that may impact study success and program implementation. mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.


Eligibility criteria:
inclusion criteria: * 18 years or older * willing and able to provide consent * willing to have their mental health clinician (mhc) share sensitive clinical information with the neurology team * able to travel to neurology clinic * have connectivity to zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as mhc office) exclusion criteria: * currently hospitalized * neurologist determines patient requires care outside of the scope of the study
effects of coffee consumption on health among adults

Conditions: Health

Summary: the purpose of this study is to research the changes of typical thermal processing food intervention on health outcome, metabolites, and gut microbiota, in order to explore the molecular mechanism of interaction between maillard reaction associated hazards and complex food matrix, and provide scientific basis and reference model for combining food nutrition and safety protection.


Eligibility criteria:
inclusion criteria: * non-smoking, non-occupational exposed healthy volunteers, 18.5\<bmi\<30 kg/m\^2, were screened. if the evaluation of disease history, blood biochemistry and blood routine was normal, the volunteers were considered healthy. exclusion criteria: * the main exclusion criteria included people with high exposure to cold and fever, recent drug intake (including dietary supplement intake), alcohol intake, vegetarians, pregnancy, high-temperature processed meat and beverages such as coffee and milk tea.

Keywords: body weight glucose lipid metabolites gut microbiota
comparing the efficacy of kt vs dn with conventional treatment for improving qol and alleviating pain in frozen shoulder

Conditions: Frozen Shoulder

Summary: "randomized control trial is our study design, we will make 2 groups group a ( 15 patients of frozen shoulder) and group b (15 patients of frozen shoulder). we will apply interventions by this way for group a kt (kinesiology taping) will be applied on frozen shoulder patients by a professional physiotherapist or certified physiotherapist according to their pain pattern in muscles (supraspinatus, infraspinatus, teres minor, deltoid, subscapularis) with conventional physiotherapy of frozen shoulder also continues on 15 patients (group a). kt will apply twice a week for 8 weeks. we can check the results of our intervention every week by using variable tools or outcome measures, measuring pain by vad (visual analog scale) and quality of life in the frozen shoulder by spadi (shoulder pain and disability index) every week. and for group b dry needling with conventional physical therapy.

"randomized control trial is our study design, we will make 2 groups group a ( 15 patients of frozen shoulder) and group b (15 patients of frozen shoulder). we will apply interventions by this way for group a kt (kinesiology taping) will be applied on frozen shoulder patients by a professional physiotherapist or certified physiotherapist according to their pain pattern in muscles (supraspinatus, infraspinatus, teres minor, deltoid, subscapularis) with conventional physiotherapy of frozen shoulder also continues on 15 patients (group a). kt will apply twice a week for 8 weeks. we can check the results of our intervention every week by using variable tools or outcome measures, measuring pain by vad (visual analog scale) and quality of life in the frozen shoulder by spadi (shoulder pain and disability index) every week. and for group b dry needling with conventional physical therapy. dn ( dry needling) is applied on trigger points in the muscles (at a time two muscles) muscles would be supraspinatus, infraspinatus, teres minor, subscapularis, deltoid, and also used in myofascial pain around the shoulder joint combine with conventional physical therapy. applying to the other 15 patients group b needles with lengths of 25 to 40mm and widths of 0.25mm will be used. each needle will be used once. 1 to 2 minutes for each trigger point. dn will apply twice a week for 8 weeks. we can check the results of our intervention every week by using variable tools or outcome measures, measuring pain by vad (visual analog scale) and quality of life in the frozen shoulder by spadi (shoulder pain and disability index) every week.

Eligibility criteria:
inclusion criteria: * diagnosed with frozen shoulder * pain in the shoulder for at least 2 months before * available trigger points for at least one muscle around the shoulder joint (supraspinatus, deltoid, infraspinatus, teres minor, and subscapularis). * limited range of motion in internal rotation, external rotation, and abduction. exclusion criteria: * patients with a history of allergy, pregnancy, or lactation period are excluded from the study.
observational study of vismodegib (erivedge) in patients treated in argentina

Conditions: Basal Cell Carcinoma

Summary: this observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (erivedge) in argentine patients. only patients with locally advanced basal cell carcinoma (labcc) or metastatic basal cell carcinoma (mbcc) will be considered in the effectiveness analysis. study duration is estimated to be approximately 12 months.


Eligibility criteria:
inclusion criteria: * argetine patients prescribed vismodegib according to standard of care and in line with summary of product characteristics (spc) and local labeling * diagnosis of labcc or mbcc for the effectiveness analysis exclusion criteria: * none specified